MX2023014676A - Composiciones de abdnaz cristalinas y metodos de elaboracion y uso de estas. - Google Patents
Composiciones de abdnaz cristalinas y metodos de elaboracion y uso de estas.Info
- Publication number
- MX2023014676A MX2023014676A MX2023014676A MX2023014676A MX2023014676A MX 2023014676 A MX2023014676 A MX 2023014676A MX 2023014676 A MX2023014676 A MX 2023014676A MX 2023014676 A MX2023014676 A MX 2023014676A MX 2023014676 A MX2023014676 A MX 2023014676A
- Authority
- MX
- Mexico
- Prior art keywords
- abdnaz
- methods
- crystalline
- compositions
- making
- Prior art date
Links
- JODKFOVZURLVTG-UHFFFAOYSA-N 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone Chemical compound [O-][N+](=O)C1([N+]([O-])=O)CN(C(=O)CBr)C1 JODKFOVZURLVTG-UHFFFAOYSA-N 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000005474 detonation Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Developmental Biology & Embryology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208631P | 2021-06-09 | 2021-06-09 | |
| PCT/US2022/032780 WO2022261284A1 (en) | 2021-06-09 | 2022-06-09 | Crystalline abdnaz compositions and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014676A true MX2023014676A (es) | 2024-02-06 |
Family
ID=84425536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014676A MX2023014676A (es) | 2021-06-09 | 2022-06-09 | Composiciones de abdnaz cristalinas y metodos de elaboracion y uso de estas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240293360A1 (https=) |
| EP (1) | EP4351567A4 (https=) |
| JP (1) | JP2024521578A (https=) |
| KR (1) | KR20240019798A (https=) |
| CN (1) | CN117835979A (https=) |
| AU (1) | AU2022289720A1 (https=) |
| BR (1) | BR112023025535A2 (https=) |
| CA (1) | CA3221351A1 (https=) |
| IL (1) | IL309043A (https=) |
| MX (1) | MX2023014676A (https=) |
| TW (1) | TW202313001A (https=) |
| WO (1) | WO2022261284A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109069420A (zh) | 2016-01-11 | 2018-12-21 | 埃皮辛特瑞柯斯公司 | 2-溴-1-(3,3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法 |
| US11510901B2 (en) | 2018-01-08 | 2022-11-29 | Epicentrx, Inc. | Methods and compositions utilizing RRx-001 combination therapy for radioprotection |
| WO2023178283A1 (en) * | 2022-03-18 | 2023-09-21 | Epicentrx, Inc. | Co-crystals of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone and methods |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507842B2 (en) * | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
| US8471041B2 (en) | 2010-02-09 | 2013-06-25 | Alliant Techsystems Inc. | Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same |
| CN109069420A (zh) | 2016-01-11 | 2018-12-21 | 埃皮辛特瑞柯斯公司 | 2-溴-1-(3,3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法 |
| US11510901B2 (en) * | 2018-01-08 | 2022-11-29 | Epicentrx, Inc. | Methods and compositions utilizing RRx-001 combination therapy for radioprotection |
-
2022
- 2022-06-09 IL IL309043A patent/IL309043A/en unknown
- 2022-06-09 EP EP22821006.8A patent/EP4351567A4/en active Pending
- 2022-06-09 BR BR112023025535A patent/BR112023025535A2/pt unknown
- 2022-06-09 CA CA3221351A patent/CA3221351A1/en active Pending
- 2022-06-09 AU AU2022289720A patent/AU2022289720A1/en active Pending
- 2022-06-09 MX MX2023014676A patent/MX2023014676A/es unknown
- 2022-06-09 JP JP2023575588A patent/JP2024521578A/ja active Pending
- 2022-06-09 CN CN202280054886.0A patent/CN117835979A/zh active Pending
- 2022-06-09 US US18/568,625 patent/US20240293360A1/en active Pending
- 2022-06-09 WO PCT/US2022/032780 patent/WO2022261284A1/en not_active Ceased
- 2022-06-09 TW TW111121521A patent/TW202313001A/zh unknown
- 2022-06-09 KR KR1020247000307A patent/KR20240019798A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202313001A (zh) | 2023-04-01 |
| AU2022289720A1 (en) | 2023-12-21 |
| US20240293360A1 (en) | 2024-09-05 |
| EP4351567A1 (en) | 2024-04-17 |
| KR20240019798A (ko) | 2024-02-14 |
| IL309043A (en) | 2024-02-01 |
| WO2022261284A1 (en) | 2022-12-15 |
| JP2024521578A (ja) | 2024-06-03 |
| CN117835979A (zh) | 2024-04-05 |
| CA3221351A1 (en) | 2022-12-15 |
| BR112023025535A2 (pt) | 2024-02-27 |
| EP4351567A4 (en) | 2025-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023014676A (es) | Composiciones de abdnaz cristalinas y metodos de elaboracion y uso de estas. | |
| MX2021014977A (es) | Composicion de nicotina en bolsitas y bolsita que la comprende. | |
| WO2020039321A3 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
| MX2020014098A (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington. | |
| EP4609865A3 (en) | Nlrp3 inhibitors | |
| MX2024000611A (es) | Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso. | |
| MX2024013464A (es) | Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos | |
| WO2007017289A3 (en) | Acyltryptophanols for fertility control | |
| MXPA05012775A (es) | Composicion acondicionadora para la piel o cabello que comprende un polimero espesante cationico hidrofobicamente modificado. | |
| MX2021003427A (es) | Nuevos oxadiazoles. | |
| EP3980050A4 (en) | <SMALLCAPS/>? ? ?p PNEUMONIA? ? ? ? METHOD OF TREATMENT OF PATIENTS WITH AN IMMUNOGENIC COMPOSITION PROTECTING AGAINST SEROTYPE 29 | |
| AU2020258568A8 (en) | CD73 inhibitors | |
| WO2020221916A3 (en) | Eutectic composition | |
| DE50112128D1 (de) | Retardpartikeldispersion | |
| EA202192646A1 (ru) | Лиофилизированная композиция, содержащая соединение бензоазепина | |
| AU2017310423A8 (en) | Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas | |
| MX2024002382A (es) | Composiciones para el cuidado personal que contienen mezclas posbioticas para reequilibrar el microbioma de la piel. | |
| MX2025003568A (es) | Compuestos y composiciones útiles como inhibidores de las proteínas inhibidoras de la apoptosis (iap) | |
| MX2023011164A (es) | Composicion amortiguadora que comprende un primer y un segundo componentes amortiguadores. | |
| DE60333633D1 (de) | Siliziumzusammensetzungen | |
| PL1677818T3 (pl) | Stabilne kompozycje wodne zawierające G-CSF | |
| DK1529021T3 (da) | Keramisk materiale med høj slagstyrke | |
| TR200200300T2 (tr) | İshali önlemeye elverişli bifidobakteriler. | |
| MX2020011070A (es) | Formas cristalinas de un compuesto. | |
| GB1441447A (en) | Electro-photographic recording medium |